Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis.
Napier
Jacqueline C
JC
Francis
Richard
R
Wright
Glyn
G
D000276:Adjuvants, Immunologic / Q000191:economics*; D003362:Cost-Benefit Analysis; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics*; D016899:Interferon-beta / Q000191:economics*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000191:economics*; D020414:Risk Sharing, Financial
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta